HEPARIN-INDUCED THROMBOCYTOPENIA SYNDROME AMONG HEMODIALYSIS PATIENTS AND DISEASE MANAGEMENT STRATEGY.

The objective of this study is to investigate the impact of heparin-induced thrombocytopenia syndrome on individuals undergoing hemodialysis. Heparin-induced thrombocytopenia in hemodialysis patients (HD-HIT) is a condition believed to occur in hemodialysis patients who experience a sudden decrease in platelet count or unexplained blood clotting, particularly when there is evidence of thrombosis in the dialysis circuit despite adequate heparin dosage. HD-HIT is thought to be caused by a drug reaction and hyper immunoglobulin syndrome. It often occurs in the third to fifth session). Although the sensitivity ELISA test can yield a positive outcome for anti-PF4/heparin complex antibodies (HIT antibodies), the diagnosis is usually verified by a functional assay. Discontinue all sources of heparin, including those used for flushing or locking catheters, promptly upon the emergence of clinical suspicion of hemolysis. Alternative non-heparin anticoagulants should be resumed for dialysis, preferably a direct thrombin inhibitor. It is critical to start treatment as soon as possible because within 30 days of ceasing heparin, thrombus formation, including a clotting circuit, can become more complicated. This study used two cases from two patients who suffer from HD-HIT, and it concluded that it is necessary to diagnose heparin-induced thrombocytopenia syndrome as soon as possible, as it may lead to a high rate of infections and deaths if left untreated since dialysis patients are frequently exposed to heparin. Their condition may lead to moderate thrombocytopenia.